Etirinotecan pegol: an option for late-stage breast cancer?

Saved in:
Bibliographic Details
Published in:The lancet oncology 2013-11, Vol.14 (12), p.1149-1151
Main Authors: Nielsen, Dorte L, Brünner, Nils
Format: Article
Language:English
Subjects:
Breast Neoplasms - drug therapy
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Female
Hematology, Oncology and Palliative Medicine
Heterocyclic Compounds, 4 or More Rings - administration & dosage
Humans
Polyethylene Glycols - administration & dosage
Topoisomerase I Inhibitors - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73
cites cdi_FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73
container_end_page 1151
container_issue 12
container_start_page 1149
container_title The lancet oncology
container_volume 14
creator Nielsen, Dorte L
Brünner, Nils
description
doi_str_mv 10.1016/S1470-2045(13)70441-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751213187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204513704418</els_id><sourcerecordid>1751210218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73</originalsourceid><addsrcrecordid>eNqNkV1rFTEQhoMo9kN_grLgTb3YNpOvzVqwSGm1UPBCvQ57kklJ3bM5JjlC_32zZ6tCb-pVhvDkzcw8hLwBegwU1Mk3EB1tGRXyCPj7jgoBrX5G9uu1aKXQ-vmuXpA9cpDzLaXQAZUvyR4TtJes7_bJ6UUJKUyxoB2mZoM3cfzQ1CpuSohT42NqxqFgm8twg80q4ZBLU1GL6ewVeeGHMePrh_OQ_Li8-H7-pb3--vnq_NN1ayWI0iqvQPeeSea73lGqGPTWs7kHISkK5pTqtKOOewZ-RTn2TrGV01bJXrqOH5KjJXeT4q8t5mLWIVscx2HCuM0GOgkMOOj_RSkD_TQqhGaMcQEVffcIvY3bNNWZZ0oJwVUnKiUXyqaYc0JvNimsh3RngJrZmdk5M7MQA9zsnJm5kbcP6dvVGt3fV38kVeBsAbAu-XfAZLINWBW4kNAW42J48ouPjxLsGKZgh_En3mH-N43JzNAlZM4AvkvQ_B7fE7ZX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1446443674</pqid></control><display><type>article</type><title>Etirinotecan pegol: an option for late-stage breast cancer?</title><source>ScienceDirect Journals</source><creator>Nielsen, Dorte L ; Brünner, Nils</creator><creatorcontrib>Nielsen, Dorte L ; Brünner, Nils</creatorcontrib><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(13)70441-8</identifier><identifier>PMID: 24095297</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Breast Neoplasms - drug therapy ; Camptothecin - administration &amp; dosage ; Camptothecin - analogs &amp; derivatives ; Female ; Hematology, Oncology and Palliative Medicine ; Heterocyclic Compounds, 4 or More Rings - administration &amp; dosage ; Humans ; Polyethylene Glycols - administration &amp; dosage ; Topoisomerase I Inhibitors - administration &amp; dosage</subject><ispartof>The lancet oncology, 2013-11, Vol.14 (12), p.1149-1151</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Jan 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73</citedby><cites>FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24095297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nielsen, Dorte L</creatorcontrib><creatorcontrib>Brünner, Nils</creatorcontrib><title>Etirinotecan pegol: an option for late-stage breast cancer?</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><subject>Breast Neoplasms - drug therapy</subject><subject>Camptothecin - administration &amp; dosage</subject><subject>Camptothecin - analogs &amp; derivatives</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Heterocyclic Compounds, 4 or More Rings - administration &amp; dosage</subject><subject>Humans</subject><subject>Polyethylene Glycols - administration &amp; dosage</subject><subject>Topoisomerase I Inhibitors - administration &amp; dosage</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNkV1rFTEQhoMo9kN_grLgTb3YNpOvzVqwSGm1UPBCvQ57kklJ3bM5JjlC_32zZ6tCb-pVhvDkzcw8hLwBegwU1Mk3EB1tGRXyCPj7jgoBrX5G9uu1aKXQ-vmuXpA9cpDzLaXQAZUvyR4TtJes7_bJ6UUJKUyxoB2mZoM3cfzQ1CpuSohT42NqxqFgm8twg80q4ZBLU1GL6ewVeeGHMePrh_OQ_Li8-H7-pb3--vnq_NN1ayWI0iqvQPeeSea73lGqGPTWs7kHISkK5pTqtKOOewZ-RTn2TrGV01bJXrqOH5KjJXeT4q8t5mLWIVscx2HCuM0GOgkMOOj_RSkD_TQqhGaMcQEVffcIvY3bNNWZZ0oJwVUnKiUXyqaYc0JvNimsh3RngJrZmdk5M7MQA9zsnJm5kbcP6dvVGt3fV38kVeBsAbAu-XfAZLINWBW4kNAW42J48ouPjxLsGKZgh_En3mH-N43JzNAlZM4AvkvQ_B7fE7ZX</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Nielsen, Dorte L</creator><creator>Brünner, Nils</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Etirinotecan pegol: an option for late-stage breast cancer?</title><author>Nielsen, Dorte L ; Brünner, Nils</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Breast Neoplasms - drug therapy</topic><topic>Camptothecin - administration &amp; dosage</topic><topic>Camptothecin - analogs &amp; derivatives</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Heterocyclic Compounds, 4 or More Rings - administration &amp; dosage</topic><topic>Humans</topic><topic>Polyethylene Glycols - administration &amp; dosage</topic><topic>Topoisomerase I Inhibitors - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, Dorte L</creatorcontrib><creatorcontrib>Brünner, Nils</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, Dorte L</au><au>Brünner, Nils</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etirinotecan pegol: an option for late-stage breast cancer?</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>14</volume><issue>12</issue><spage>1149</spage><epage>1151</epage><pages>1149-1151</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24095297</pmid><doi>10.1016/S1470-2045(13)70441-8</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2013-11, Vol.14 (12), p.1149-1151
issn 1470-2045
1474-5488
language eng
recordid cdi_proquest_miscellaneous_1751213187
source ScienceDirect Journals
subjects Breast Neoplasms - drug therapy
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Female
Hematology, Oncology and Palliative Medicine
Heterocyclic Compounds, 4 or More Rings - administration & dosage
Humans
Polyethylene Glycols - administration & dosage
Topoisomerase I Inhibitors - administration & dosage
title Etirinotecan pegol: an option for late-stage breast cancer?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A38%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etirinotecan%20pegol:%20an%20option%20for%20late-stage%20breast%20cancer?&rft.jtitle=The%20lancet%20oncology&rft.au=Nielsen,%20Dorte%20L&rft.date=2013-11-01&rft.volume=14&rft.issue=12&rft.spage=1149&rft.epage=1151&rft.pages=1149-1151&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(13)70441-8&rft_dat=%3Cproquest_cross%3E1751210218%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c514t-6f6189f252f79d006219cf22409450e42d6678d0d3f21fb03e9d62bd8c6595d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1446443674&rft_id=info:pmid/24095297&rfr_iscdi=true